Advanced Search

Advances in targeted chemotherapy using MRI-guided focused ultrasound to disrupt the blood-brain barrier

Research and Teaching Output of the MIT Community

Show simple item record

dc.contributor.advisor Kullervo Hynynen. en_US Treat, Lisa Hsu en_US
dc.contributor.other Harvard University--MIT Division of Health Sciences and Technology. en_US 2009-10-01T15:51:54Z 2009-10-01T15:51:54Z 2009 en_US 2009 en_US
dc.description Thesis (Ph. D.)--Harvard-MIT Division of Health Sciences and Technology, 2009. en_US
dc.description Includes bibliographical references (p. 107-121). en_US
dc.description.abstract The clinical application of chemotherapy to brain malignancies has been severely limited because many potential therapeutic agents are typically unable to penetrate the blood-brain barrier (BBB). A novel approach to overcome this barrier uses focused ultrasound to induce localized BBB disruption in a targeted region of the brain and magnetic resonance imaging (MRI) to guide and monitor the procedure. The purpose of this thesis was to develop a technique using MRI-guided focused ultrasound for trans bbb drug delivery applications. This thesis demonstrates that MRI-guided focused ultrasound can be used to achieve consistent and reproducible BBB disruption without invasive craniotomy in rats, to enable doxorubicin to accumulate in normal brain at clinically therapeutic levels, and to increase the antitumoral efficacy of doxorubicin in a rodent model of aggressive glioma. Using a microbubble-based ultrasonographic contrast agent, focal BBB opening was consistently achieved using transcranial focal pressures of 1.2 MPa or greater; locations in the posterior brain exhibited consistent BBB disruption with applied focal pressures of 0.8 MPa or greater. When combined with systemic administration of liposomal doxorubicin, we achieved local drug concentrations of 900 ± 300 ng/g tissue in the brain with minimal tissue effects, and up to 5400 ± 700 ng/g tissue with more significant tissue damage, while accumulation in non-targeted contralateral brain tissue remained significantly lower (p < 0.001). In addition, MRI signal enhancement in the sonicated region correlated strongly with doxorubicin concentration in tissue (r = 0.87), suggesting that contrast-enhanced MRI may provide useful feedback on drug penetration. en_US
dc.description.abstract (cont.) Finally, glioma-bearing rats treated with ultrasound-enhanced chemotherapy exhibited significantly longer median survival times (31 versus 25 days; p = 0.0007) and slower tumor growth (average tumor volume doubling time, 3.7 ± 0.5 days, versus 2.3 ± 0.3 days) than nontreated rats; rats which received standard intravenous chemotherapy showed no significant difference in survival or tumor growth rate. In sum, this thesis research provides pre-clinical data toward the development of MRI-guided focused ultrasound as a noninvasive method for the delivery of agents such as doxorubicin across the BBB to treat patients with diseases of the central nervous system. en_US
dc.description.statementofresponsibility by Lisa Hsu Treat. en_US
dc.format.extent 121 p. en_US
dc.language.iso eng en_US
dc.publisher Massachusetts Institute of Technology en_US
dc.rights M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. en_US
dc.rights.uri en_US
dc.subject Harvard University--MIT Division of Health Sciences and Technology. en_US
dc.title Advances in targeted chemotherapy using MRI-guided focused ultrasound to disrupt the blood-brain barrier en_US
dc.type Thesis en_US Ph.D. en_US
dc.contributor.department Harvard University--MIT Division of Health Sciences and Technology. en_US
dc.identifier.oclc 430341277 en_US

Files in this item

Name Size Format Description
430341277-MIT.pdf 28.41Mb PDF Full printable version

This item appears in the following Collection(s)

Show simple item record